Inventage Lab unveiled its next-generation obesity drug platform technology in a poster presentation at the American Diabetes Association (ADA) Annual Scientific Sessions, held from Friday to Monday in Chicago, the U.S..

The presentation highlighted preclinical data from the company's semaglutide and tirzepatide-based one-month-long injectables (IVL3021 and IVL3024) and semaglutide oral (IVL3027).

According to the presentation, the long-acting injectable based on proprietary microsphere technology was highlighted for its uniformity of particle size and suppressed initial over-release, resulting in stable drug release. IVL3027, an oral semaglutide formulation, was also highlighted by attendees for its significantly higher bioavailability and sustained drug release for one week compared to existing oral formulations.

Based on the high level of interest from the global market, Inventage Lab plans to accelerate global technology transfer and co-development collaboration discussions following last week's BIO USA 2025 in Boston and the ADA meeting.

Inventage Lab attended BIO USA 2025 in Boston as a standalone booth before the ADA meeting. It held partnering meetings with Genentech, AbbVie, Sanofi, Roche, and LEO Pharma, including a follow-up meeting with Novo Nordisk.

The company plans to strengthen strategic partnerships in key markets, including the U.S. and Europe, and refine the global commercialization roadmap for its pipeline based on its platform technologies IVL-DrugFluidic and IVL-PePOFluidic.